Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Bhandari

Showing results (181-190 of 311) with videos related to

Pageof 32
Sort By:
Journal of Crohn'S & Colitis|May 17, 2018
Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe DiseaseWilliam J Sandborn, Bal R Bhandari, Charles Randall, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 24, 2023
Transcription factor expression repertoire basis for epigenetic and transcriptional subtypes of colorectal cancersYuba R Bhandari, Vinod Krishna, Rachael Powers, et al.
Journal of Crohn'S & Colitis|May 31, 2018
A Phase 2, Randomized, Placebo-Controlled Study Evaluating Matrix Metalloproteinase-9 Inhibitor, Andecaliximab, in Patients With Moderately to Severely Active Crohn's DiseaseStefan Schreiber, Corey A Siegel, Keith A Friedenberg, et al.
Gastroenterology|September 8, 2019
Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative ColitisWilliam J Sandborn, Marc Ferrante, Bal R Bhandari, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 20, 2020
Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative ColitisWilliam J Sandborn, Marc Ferrante, Bal R Bhandari, et al.
Macromolecular Rapid Communications|December 22, 2018
Combinatorial Synthesis of Peptoid Arrays via Laser-Based Stacking of Multiple Polymer NanolayersDaniela S Mattes, Bettina Streit, Dhaka R Bhandari, et al.
Journal of Hepatology|October 10, 2020
Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosisCatherine Frenette, Zeid Kayali, Edward Mena, et al.
Nature|December 18, 2024
Determining structures of RNA conformers using AFM and deep neural networksMaximilia F S Degenhardt, Hermann F Degenhardt, Yuba R Bhandari, et al.
Alimentary Pharmacology & Therapeutics|March 4, 2022
Editorial: protecting hypoxia-inducible factor 1a and gut integrity with GB004-a promising therapeutic approach for ulcerative colitis? Authors' replySilvio Danese, Barrett G Levesque, Brian G Feagan, et al.
Gene Therapy|October 20, 2006
Aerosol delivery of Akt controls protein translation in the lungs of dual luciferase reporter miceA M Tehrani, S-K Hwang, T-H Kim, et al.
Pageof 32

Showing results (181-190 of 311) with videos related to

Sort By:
Pageof 32
Journal of Crohn'S & Colitis|May 17, 2018
Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe DiseaseWilliam J Sandborn, Bal R Bhandari, Charles Randall, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 24, 2023
Transcription factor expression repertoire basis for epigenetic and transcriptional subtypes of colorectal cancersYuba R Bhandari, Vinod Krishna, Rachael Powers, et al.
Journal of Crohn'S & Colitis|May 31, 2018
A Phase 2, Randomized, Placebo-Controlled Study Evaluating Matrix Metalloproteinase-9 Inhibitor, Andecaliximab, in Patients With Moderately to Severely Active Crohn's DiseaseStefan Schreiber, Corey A Siegel, Keith A Friedenberg, et al.
Gastroenterology|September 8, 2019
Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative ColitisWilliam J Sandborn, Marc Ferrante, Bal R Bhandari, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 20, 2020
Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative ColitisWilliam J Sandborn, Marc Ferrante, Bal R Bhandari, et al.
Macromolecular Rapid Communications|December 22, 2018
Combinatorial Synthesis of Peptoid Arrays via Laser-Based Stacking of Multiple Polymer NanolayersDaniela S Mattes, Bettina Streit, Dhaka R Bhandari, et al.
Journal of Hepatology|October 10, 2020
Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosisCatherine Frenette, Zeid Kayali, Edward Mena, et al.
Nature|December 18, 2024
Determining structures of RNA conformers using AFM and deep neural networksMaximilia F S Degenhardt, Hermann F Degenhardt, Yuba R Bhandari, et al.
Alimentary Pharmacology & Therapeutics|March 4, 2022
Editorial: protecting hypoxia-inducible factor 1a and gut integrity with GB004-a promising therapeutic approach for ulcerative colitis? Authors' replySilvio Danese, Barrett G Levesque, Brian G Feagan, et al.
Gene Therapy|October 20, 2006
Aerosol delivery of Akt controls protein translation in the lungs of dual luciferase reporter miceA M Tehrani, S-K Hwang, T-H Kim, et al.
Pageof 32